Controls for hmunogold Labeling
It is essential to prevent and identify spurious probe deposition during immunogold labeling for electron microscopy, as in all immunocytochemical procedures, so that genuine epitope distribution is revealed. The specificity of the primary antibody against the antigen of interest must be confirmed before use, and a variety of strategies can be employed during the labeling process to minimize nonspecific binding to the tissue and section components by the primary antibody, the linking antibodies, and the gold probe. Of particular concern is the identification of nonspecific binding (background) with a restricted distribution that mimics a genuine labeling pattern. Therefore, controls must be included in the test schedule to determine binding specificity and to act as a procedural check, and these are essential for the validation of all experimental results. Despite this requirement, it is possible to find in the literature reports in which no controls are described or the controls performed were inadequate.
The range of controls required for immunogold labeling of sectioned material for electron microscopy can be summarized as follows:
Omission of the Primary Antibody. The primary antibody is omitted from the test protocol and the sections are incubated with the antibody diluent only, followed by the gold probe. This identifies nonspecific binding by the gold probe. If a linking antibody is used, both the primary and the linking antibody must be omitted.
For immunocytochemical procedures, antibodies are presented in a variety of media ranging from whole serum to buffers or, in the case of monoclonal antibodies, tissue culture medium or ascites fluid. These media may contain additives such as bovine serum albumin or fetal calf serum. Except for whole serum, it is unlikely that these media or additives will cause nonspecific binding of antibodies or gold probes. However, if this is suspected, additional controls can be included in which the primary is omitted and the tissue is incubated with antibody diluent containing the medium or additive at the same concentration as it would be in the primary antibody test solution.
Substitution of the Primary Antibody. A wide range of factors other than antibody crossreactivity can cause antibodies to bind nonspecifically to tissue sections (I), including, in some circumstances, incubation with sodium metaperiodate, a treatment frequently used to revive tissue antigenicity (2). To identify such binding it is essential to carry out a test in which the primary antibody is substituted with a similar antibody directed against a different epitope. This control should replicate the test conditions as closely as possible. Therefore, the substitute must derive from the same animal species, it must be applied at the same or marginally higher (not lower) concentration, and it must be from the same immunoglobulin (Ig) class and subclass. For polyclonal antibodies, the best substitute is pre-immune serum from the same individual in which the antibody was raised, but pooled normal serum (non-immune serum) from other individuals is also acceptable. Additional possibilities are a whole serum-based antibody against an epitope not present in the tissue (an inappropriate antibody) or a similarly based antibody against an epitope present in the sample but with a known distribution (in which case the antibody doubles as a positive procedural control). An affinity-purified polyclonal antibody is less acceptable as a substitute for a whole serum-based antibody because the range of antibod-Vol. 41, No. 12, pp. 1869 41, No. 12, pp. -1870 41, No. 12, pp. , 1993 Priated an US.A.
ies in the substitute will be restricted and, if the primary has been treated (e.g., to give an IgG cut), the substituting antibody should have been treated similarly. Monoclonal antibodies can be substituted by an inappropriate antibody or an antibody to a tissue epitope with a known distribution. In both cases the hybridoma producing the antibody should derive from the same animal species, the same antibody concentration should be used, and the antibody should be of the same class and subclass. In all cases it is advisable that the presenting medium of the substituting antibody contain similar additives to the primary so that after dilution the media have a similar ability to suppress background.
Absorption of the Primary Antibody with Target Antigen. The primary antibody is absorbed with purified target antigen and the resulting solution is used as a substitute for the primary antibody. When affinitypurified antisera or monodonah are absorbed in this way, all antibody should be removed, and if whole serum or Ig fractions are treated only nonspecific antibodies should remain. This is a negative control principally intended to detect contaminating antibodies that might bind to epitopes other than the target, thus indicating specificity of reaction. The usefulness of this control is completely dependent on the purity and quality of the antigen used for antibody production and absorption, and the procedure is meaningless unless this is ensured. This strategy also assumes that there is no crossreactivity with similar epitopes. To idenufy nonspecific binding by the primary, controls with immunoabsorbed antibodies should always be carried out in conjunction with controls in which an alternative antibody is substituted for the primary. This is particularly important when &inity-purifed antibodies or monoclonals are used and hmunoabsorpcion is expected to remove all antibody from the antiserum or medium.
Removal of Antigen. In certain situations it is possible to remove the epitope of interest from the tissue by enzymatic digestion or other means. This provides an additional negative control which helps to confirm antibody specificity.
Positive Controls.
A known positive should be tested by the same technique to avoid the possibility of a false negative. This acts as a procedural control and tests the effectiveness of the labeling strategy. The inclusion of such controls is rarely described and it is usually assumed that the labeling procedure has been tested previously and is known to be effective. When the epitope concerned has a poorly defined or unknown distribution, it is best to confirm the distribution with an alternative high-sensitivity technique. This helps to avoid the possibility of a false negative in the presence of some positive areas. When the test is carried out to confirm the absence of an epitope, a positive control is essential to exclude the possibility of a false negative.
In conclusion, in addition to tests that may be required to confirm epitope specificity and exclude false negatives, all immunogold labeling experiments should include controls designed to identify nonspecific probe deposition that mimics genuine positive labeling. These controls are: (a) substitution ofthe primary antibody by an alternative to identlfy nonspecific antibody binding; and (b) a control in which the primary and link antibodies are omitted to confirm link antibody and gold probe specificity.
